Int. Journal of Clinical Pharmacology and Therapeutics, Volume 43 - October (463 - 471)

Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration
M. Meyer, B. Jilma, R. Zahlten, G. Wolff
1 Revotar Biopharmaceuticals AG, Hennigsdorf, Germany, and 2 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Add to Cart  

 

DOI 10.5414/CPP43463

Abstract

Objective: Bimosiamose is a novel synthetic panselectin antagonist being developed for the treatment of acute and chronic inflammatory disorders. Therefore, we have studied the pharmacokinetics and tolerability and determined the pharmacokinetically relevant physicochemical characteristics of bimosiamose. Method: A randomized, double-blind, placebo-controlled dose-escalation trial in healthy male subjects has been carried out. The subjects received intravenous infusions of 0.5 ? 30 mg/kg bimosiamose disodium. Results and conclusions: The maximum plasma concentration (Cmax) was 675

Author Details

Authors

Departments

  • 1 Revotar Biopharmaceuticals AG, Hennigsdorf, Germany, and
  • 2 Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Address

Dr. M. Meyer Revotar Biopharmaceuticals AG Neuendorfstra
Email: [email protected]

Log in for Subscribers

Citation

M. Meyer, B. Jilma, R. Zahlten and G. Wolff. Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration. 2005; 43: 463-471. doi: 10.5414/CPP43463.

###article_not_exists_msg###

Warenkorb Übersicht

Warenkorb Übersicht
Typ Anz Rabatt MwSt Preis
Der Warenkorb ist leer
Ihr Warenkorb